Delos Capital
Delos Capital is a venture capital firm dedicated to empowering life sciences leaders to transform bold ideas into medical breakthroughs. The firm leverages a diverse skill set and a global network to support groundbreaking innovations aimed at improving lives worldwide. Since its founding in 2014, Delos Capital has been committed to investing in visionary life sciences companies that advance medicine, yielding multiple new drug approvals and device clearances by regulatory bodies like the FDA.
Services
Support at All Stages
Delos Capital provides deep industry experience, creativity, and candid support to visionary biotech teams at all stages of their journeys.
Guided by the Science
The firm diligently connects cutting-edge science with well-defined clinical needs, ensuring that investments are scientifically sound and meet unmet medical needs.
Committed to the Cause
Delos Capital's investments have led to multiple new drug approvals and device clearances, with a commitment to building on this legacy to continually improve lives globally.
Support at All Stages
Delos Capital provides deep industry experience, creativity, and candid support to visionary biotech teams at all stages of their journeys.
Guided by the Science
The firm diligently connects cutting-edge science with well-defined clinical needs, ensuring that investments are scientifically sound and meet unmet medical needs.
Committed to the Cause
Delos Capital's investments have led to multiple new drug approvals and device clearances, with a commitment to building on this legacy to continually improve lives globally.
Portfolio
Developing a deep, clinical-stage portfolio of innovative therapeutics for broad inflammatory & immunology indications.
#Biopharmaceuticals
Developing redosable, durable, mRNA-based genetic medicines delivered via lipid nanoparticles.
#Genetic Medicines
Announced $175 million oversubscribed Series C financing to advance robust clinical pipeline of radiopharmaceuticals.
#Oncology
Completed $30MM equity financing to advance clinical trials and commercialization readiness.
#Medical Technology
Developing a deep, clinical-stage portfolio of innovative therapeutics for broad inflammatory & immunology indications.
#Biopharmaceuticals
Developing redosable, durable, mRNA-based genetic medicines delivered via lipid nanoparticles.
#Genetic Medicines
Announced $175 million oversubscribed Series C financing to advance robust clinical pipeline of radiopharmaceuticals.
#Oncology
Completed $30MM equity financing to advance clinical trials and commercialization readiness.
#Medical Technology